The Association between Daily Dietary Intake of Riboflavin and Lung Function Impairment Related with Dibutyl Phthalate Exposure and the Possible Mechanism

Jilei Lin 1,†, Siying Cheng 2,†, Jing Zhang 1,†, Shuhua Yuan 1, Lei Zhang 1, Jinhong Wu 1, Jiande Chen 1, Mingyu Tang 1, Yabin Hu 3, Shilu Tong 3, Liebin Zhao 4,*, and Yong Yin 1,4,5,*

1 Department of Respiratory Medicine, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China; jilei_lin@163.com (J.L.); zhangjing@scmc.com.cn (J.Z.); yuanshuhua@scmc.com.cn (S.Y.); zhanglei@scmc.com.cn (L.Z.); wujinhong@scmc.com.cn (J.W.); chenjiande@scmc.com.cn (J.C.); tangmingyu@scmc.com.cn (M.T.)
2 Department of Neurology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China; chengsiying1992@163.com
3 Department of Clinical Epidemiology and Biostatistics, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China; huyabin@scmc.com.cn (Y.H.); tongshilu@scmc.com.cn (S.T.)
4 Shanghai Engineering Research Center of Intelligence Pediatrics (SERCIP), Shanghai 200092, China
5 Pediatric AI Clinical Application and Research Center, Shanghai Children’s Medical Center, Shanghai 200092, China
* Correspondence: zhaoliebin@126.com (L.Z.); yinyong9999@163.com (Y.Y.)
† These authors contributed equally to this work.

Abstract: This study aimed to evaluate the relationship between the daily dietary intake of riboflavin (DDIR) and impaired lung function associated with dibutyl phthalate (DBP) exposure. Data of 4631 adults in this national cross-sectional survey were included. Urinary mono-benzyl phthalate (MBP) was used to evaluate the level of DBP exposure. The ln-transformed urinary creatinine-corrected MBP (ln(MBP/UCr)) level was used in the statistical models. High DDIR was defined as the DDIR ≥ 1.8 mg per day. The results of lung function impairment and high monocytes were significantly higher in the highest MBP group compared with the lowest MBP group. A significant interaction between ln(MBP/UCr) and DDIR (Pinteraction = 0.029) was detected for the risk of lung function impairment. The risk of lung function impairment (ORquartiles4 vs. 1 1.85, 95% CI, 1.27–2.71; P trend = 0.018) and high neutrophils (ORquartiles4 vs. 1 1.45, 95% CI, 1.06–1.97; P trend = 0.018) was significantly higher in the highest vs. the lowest quartile of MBP in participants with low/normal DDIR but not in participants with high DDIR. The results of this study showed that high DDIR was associated with less lung function impairment related with DBP exposure, and the inhibiting of the neutrophil recruitment might be the potential mechanism.

Keywords: dibutyl phthalate; riboflavin; neutrophils; monocytes; National Health and Nutrition Examination Survey

1. Introduction

Phthalates are widely used as plasticizers in polyvinyl chloride products, medical devices, and toys [1]. The serious environmental contamination caused by phthalates have attracted extensive attention. Previous studies suggested that phthalates metabolites can be easily detected in human biospecimens due to the high exposure of phthalates in daily life [2,3]. The relationship between concentration of these metabolites and diseases was explored in many previous studies [4–6].

One previous study suggested that the concentration of phthalates metabolites in lung of rats is low [7], and there were limited studies on the relationship between phthalates
exposure and respiratory diseases of human in past decades. In recent years, some studies have found the concentration of dibutyl phthalate (DBP) was high in indoor air, and its inhalation may contribute to more than 20% of the daily internal dose of the phthalates [8,9]. Therefore, researchers have realized that phthalates were related with the development of respiratory diseases in recent years [6,10]. Although there was no direct approach to detect phthalate concentration in human lung tissues, urinary phthalate concentration has been demonstrated to be a good biomarker of phthalates exposure. Mono-benzyl phthalate (MBP) is one of the main metabolites of DBP, and urinary MBP was usually used to evaluate the level of DBP exposure. It was reported that exposure to DBP was associated with the oxidative stress and type 2 immune response in the airway, which could contribute to the development of airway hyperresponsiveness in mice [11,12]. However, there is no population-based study to explore or verify these theories.

Riboflavin, a water-soluble vitamin, is critical for cellular growth and function. It can be obtained from various foods and participates in antioxidant and anti-inflammatory processes [13]. Previous studies showed that patients who smoke or those with COPD have lower riboflavin status compared with normal people, and COPD patients with lower riboflavin status have lower FEV1% and more serious clinical symptoms [14]. However, the role of riboflavin intake on the lung function impairment associated with phthalates exposure was unknown.

Considering the factors above, this population-based study aimed to evaluate two topics including the relationship between DBP exposure and lung function, and the role of daily dietary intake of riboflavin (DDIR) on lung function impairment related with DBP exposure in U.S. population.

2. Materials and Methods

2.1. Study Population

In this study, we used publicly available data from the National Health and Nutrition Examination Survey (NHANES) conducted by the CDC. This national cross-sectional survey was designed to collect information on the health and nutrition status of the American population. The detailed information about the NHANES study can be found online at http://www.cdc.gov/nchs/nhanes.htm (accessed on 1 February 2022). We examined national cross-sectional data in three consecutive NHANES cycles (2007–2008, 2009–2010, 2011–2012) from the NHANES database. Data on riboflavin intake, alternatives of phthalates, and lung function of adults (≥18 years old) were retrieved from the database. The informed consents of this study were obtained, and the ethics was approved by the National Center for Health Statistics Research Ethics Review Board.

2.2. Data Extraction

The collected data included demographic information, underlying disease, daily riboflavin intake from foods and beverages (including all types of water), urinary phthalate metabolites, and lung function. Finally, age (18–45, 45–60, and ≥60 years old), sex (man, woman), body mass index (BMI, <18.5, 18.5–25, 25–30, and ≥30 kg/m²), race (Hispanic: Mexican American and other Hispanic; non-Hispanic: non-Hispanic White, non-Hispanic Black, and other race), level of education (below high school, high school, above high school), smoking (current, former, never), history of diabetes (yes, no), history of hypertension (yes, no), lung function, concentration of urinary phthalate metabolites (see the following definition), and count and percentage of blood cells were included.

2.3. Exposure of Phthalate

Urinary phthalate metabolites were used to evaluate the exposure of phthalate and its alternatives in humans. We included 12 kinds of urinary phthalate metabolites (mono carboxyisononyl phthalate, mono carboxyisoctyl phthalate, mono-2-ethyl-5-carboxypentyl phthalate, mono-n-butyl phthalate, mono-(3-carboxypropyl) phthalate, mono-ethyl phthalate, mono-(2-ethyl-5-hydroxyhexyl) phthalate, mono-(2-ethyl)-hexyl phthalate, mono-
isobutyl phthalate, mono-isononyl phthalate, mono-(2-ethyl-5-oxohexyl) phthalate, and mono-benzyl phthalate), which were tested in all the NHANES cycles from 2007 to 2012. The methodology of detections for urinary phthalate metabolites was described on the NHANES official website (www.cdc.gov/Nchs/Nhanes/2011-2012/PHTHTE_G.htm) (accessed on 1 February 2022). The value below the lower limit of detection was divided by square root of 2. Urinary MBP was used to evaluate the level of DBP exposure. In this study, the value of diethylhexyl phthalates was calculated as the sum of the concentrations of mono-(2-ethyl-5-carboxypentyl) phthalate, mono(2-ethyl-5-hydroxyhexyl) phthalate, and mono(2-ethyl-5-oxohexyl) phthalate. We used urinary creatinine-corrected urinary phthalate metabolites levels in the statistical models to reduce the differences of urinary phthalate metabolites caused by different urinary flow. Creatinine-adjusted urinary phthalate metabolites were also ln-transformed in the analysis. Compared with the group with normal lung function, MBP was the only significantly increased urinary phthalate metabolites in the group with declined lung function, so we used MBP as the main research object in the whole study.

2.4. Lung Function and Fractional Exhaled Nitrous Oxide

Spirometry was conducted for the included participants in this survey during 2007–2012; meanwhile, individual fractional exhaled nitrous oxide (FeNO) was also measured. The spirometers used in the study were Ohio 822/827 dry-rolling seal volume spirometers. The procedures of spirometry were based on the current standards for pulmonary function, equipment, testing, and interpretation set by the American Thoracic Society. The participants’ spirometry results were evaluated by a computerized algorithm. Examinees with an FEV1/FVC% less than the lower limit of normal determined for his or her age, sex, weight, height, and race/ethnicity or those who had a FEV1/FVC% less than 70% were considered as people with lung function impairment. Lower limit of normal for the FEV1/FVC was calculated based on the sample persons’ age, sex, height, and race/ethnicity [15]. The value of FeNO was calculated as the mean of two reproducible FeNO measurements in parts per billion (ppb). The FeNO data were used to estimate the airway inflammation, and the potential airway inflammation was defined as FeNO ≥ 25 ppb. The methodology about spirometry was described on the NHANES official website (www.cdc.gov/Nchs/Nhanes/2011-2012/SPXRAW_G.htm) (accessed on 1 February 2022).

2.5. Daily Dietary Intake of Riboflavin

The 24 h detailed dietary intake information was collected in the dietary interview. United States Department of Agriculture’s Food and Nutrient Database for Dietary Studies (FNDDS) was used to calculate the nutrient intakes (http://www.ars.usda.gov/ba/bhnrc/fsrg) (accessed on 1 February 2022). The FNDDS includes comprehensive information that can be used to code individual foods and portion sizes reported by participants and also includes nutrient values for calculating nutrient intakes. Foods/beverages or portions that could not be matched to items in the database were resolved by scientists. Finally, the daily dietary intake of riboflavin (DDIR) in milligram (mg) was calculated from the total food and beverages consumption. The median of DDIR was 1.83 mg in this study, and the recommended intake of daily intake of riboflavin was 1.4~1.8 mg, and therefore, we defined high DDIR as DDIR ≥ 1.8 mg.

2.6. Statistical Analysis

Continuous variables were presented as means ± standard deviation (SD). Categorical variables were analyzed by the χ2 test or the Fisher’s exact test, as appropriate. Logistic regression was applied to estimate odds ratio (ORs) and 95% confidence intervals (CIs) for the association between risk of lung function impairment and urinary MBP. We divided the included participants into quartiles of ln(MBP), with the lowest quartile being the reference group. The linear trends in risk estimates across quartiles of ln(MBP/UCr) were calculated.
by one degree-of-freedom trend test [16]. We adjusted for several confounders in our logistic models. Specifically, model 1 was unadjusted, model 2 was adjusted for characteristics (sex, age, race, education); model 3 was adjusted for characteristics and underlying diseases (sex, age, race, education, sex, BMI, history of diabetes, smoke, history of hypertension, and respiratory diseases); and model 4 was adjusted for variables with significant p-values of linear trends (sex, age, race, education, smoke, history of hypertension, and respiratory diseases). Prespecified subgroup analyses were conducted to assess whether the observed association of risk of lung function impairment and urinary MBP was modified by sex, age, race, education, sex, BMI, history of diabetes, smoke, history of hypertension, respiratory diseases, and DDIF status. The ORs were adjusted for sex, age, race, education, smoke, history of hypertension, and respiratory diseases in subgroup analysis. A $P_{\text{interaction}}$ was calculated by a likelihood ratio test, which compared the models with and without interaction terms. Restricted cubic spline regression with 3 knots at the 10th, 50th, and 90th percentiles was used to explore the potential dose–response relationship between ln(MBP/UCr) and lung function impairment. The reference level was set at 6.31. A $P_{\text{nonlinearity}}$ was obtained by testing the null hypothesis that regression coefficients of the second splines are equal to zero. $p < 0.05$ was considered to indicate statistical significance. All statistical analyses were performed using SPSS 25.0 software and R 4.10 software.

3. Results
3.1. Characteristics of the Included Population

In general, 30,422 subjects were invited to participate in the NHANES cross-sectional study between 2005 and 2018. Participants without the results of urinary phthalate metabolites and spirometry were excluded. 4631 participants aged $\geq$18 years old were finally included in this study. The detailed information of screening process was shown in Figure 1. Participants aged 18–45 years old accounted for the highest proportion of all the study population (50.62%). The mean ± SD of DDIF in all participants was 2.10 ± 1.35 mg. There were 3889 cases (1943 men and 1944 women) in the normal group and 742 cases (432 men and 310 women) in the lung function impairment group (Table 1, Tables S1 and S2). There were significant differences of age, BMI, race, education, alcoholic drinks, current smoking, history of diabetes, and history of hypertension between the normal and lung function impairment groups. Among 12 kinds of urinary phthalate metabolites, only MBP was significantly higher in the lung function impairment group compared with the normal group (Table S1).

Figure 1. The study flow chart of identifying eligible subjects.
Table 1. The characteristics of study population and the difference between groups with and without lung function impairment.

|                                | Total          | Lung Function Impairment |        |        | p       |
|--------------------------------|----------------|--------------------------|-------|-------|---------|
|                                |                | No                        | No (%)| Yes   | (%)     |
| **Sample size**                | 4631           | 3889                      |        | 742   |         |
| **Sex (men, %)**               |                | 2375 (51.28%)             |        | 1943 (49.96%) | 432 (58.22%) | <0.001 |
| Age (years old)                |                |                           |       |       | <0.001  |
| 18–45                          | 2344 (50.62%)  | 2100 (54.00%)             |        | 244   (32.88%) |         |        |
| 45–60                          | 1135 (24.51%)  | 957 (24.61%)              |        | 178   (23.99%) |         |        |
| ≥60                            | 1152 (24.88%)  | 832 (21.39%)              |        | 320   (43.13%) |         |        |
| **BMI (kg/m²)**                |                |                           |       |       | <0.001  |
| <18.5                          | 83 (1.79%)     | 69 (1.78%)                |        | 14    (1.90%) |         |        |
| 18.5–25                        | 1341 (28.96%)  | 1081 (27.96%)             |        | 260   (35.28%) |         |        |
| 25–30                          | 1534 (33.12%)  | 1295 (33.50%)             |        | 239   (32.43%) |         |        |
| ≥30                            | 1645 (35.52%)  | 1421 (36.76%)             |        | 224   (30.39%) |         |        |
| **Race**                       |                |                           |       |       | <0.001  |
| Mexican American               | 734 (15.85%)   | 667 (17.15%)              |        | 67    (9.03%) |         |        |
| Other Hispanic                 | 483 (10.43%)   | 424 (10.90%)              |        | 59    (7.95%) |         |        |
| Non-Hispanic White             | 1955 (42.22%)  | 1535 (39.47%)             |        | 420   (56.60%) |         |        |
| Non-Hispanic Black             | 1031 (22.26%)  | 873 (22.45%)              |        | 158   (21.29%) |         |        |
| Other Race                     | 428 (9.24%)    | 390 (10.03%)              |        | 38    (5.12%) |         |        |
| **Education**                  |                |                           |       |       | 0.014   |
| Below high school              | 1187 (25.65%)  | 985 (25.35%)              |        | 202   (27.26%) |         |        |
| High school                    | 1078 (23.30%)  | 882 (22.70%)              |        | 196   (26.45%) |         |        |
| Above high school              | 2362 (51.05%)  | 2019 (51.96%)             |        | 343   (46.29%) |         |        |
| **Smoking status (yes, %)**    |                |                           |       |       | <0.001  |
| Never                          | 2383 (54.79%)  | 2140 (58.86%)             |        | 243   (34.08%) |         |        |
| Former                         | 977 (22.46%)   | 758 (20.85%)              |        | 219   (30.72%) |         |        |
| Current                        | 989 (22.74%)   | 738 (20.30%)              |        | 251   (35.20%) |         |        |
| Respiratory disease (yes, %)   | 565 (12.20%)   | 396 (10.18%)              |        | 169   (22.78%) | <0.001 |        |
| History of diabetes (yes, %)   | 466 (10.07%)   | 373 (9.60%)               |        | 93    (12.53%) | 0.015  |        |
| History of hypertension (yes, %)| 1376 (29.74%) | 1109 (28.54%)             |        | 267   (36.03%) | <0.001 |        |
| Mono-benzyl phthalate          | 6.32 ± 0.98    | 6.30 ± 0.98               |        | 6.40 ± 0.96 | 0.007  |        |
| Lung function impairment       | 742 (16.02%)   | 0 (0%)                    |        | 742   (100%) | 0.039  |        |
| FeNO                           | 16.91 ± 15.05  | 16.67 ± 14.31             |        | 18.18 ± 18.39 |         |        |
| **Blood cells**                |                |                           |       |       |         |
| Monocyte number (cells/µL)     | 529.34 ± 183.65| 524.46 ± 180.27           |        | 554.93 ± 198.65 | <0.001 |        |
| Neutrophils number (cells/µL)  | 4259.81 ± 2071.89| 4227.04 ± 2127.74       |        | 4431.69 ± 1741.19 | 0.006  |        |
| Daily dietary intake of riboflavin (mg) | 2.10 ± 1.35 | 2.09 ± 1.33 | 2.19 ± 1.44 | 0.077 |

Lung function impairment: best test FEV1/FVC ratio below the lower limit of normal and/or less than 70%. BMI, body mass index; FeNO, fractional exhaled nitrous oxide.

3.2. Subjects with Different Level of Urinary MBP

We divided study population into 4 groups by the quartiles of ln(MBP(ng/L)/UCr(g/dL)). The clinical characteristics, lung function, and the blood cells of the four groups are shown in Table 2. Participants in the highest vs. the lowest quartiles of MBP were younger; more likely to be non-Hispanic White; more likely to have a higher BMI, higher eosinophils, and neutrophils number and percent; and more likely to have a higher risk of respiratory diseases and lung function impairment (all $p_{trend} < 0.05$). (Table 2 and Table S3). However, there was no linear trend of FeNO among four groups ($p_{trend} = 0.092$).
Table 2. The clinical characteristics of study population according to the concentration of urinary MBP.

| Characteristics                  | Quartile of ln(MBP/UCr), Range (Median) | P_{trend} |
|----------------------------------|----------------------------------------|-----------|
|                                  | 2.15–5.69 (5.23) | 5.69–6.31 (6.03) | 6.31–6.93 (6.59) | 6.93–10.20 (7.40) |
| Sample size                      | 1164                     | 1155                  | 1151                  | 1161                       |            |
| Sex (men, %)                     | 689 (59.19%)             | 615 (53.25%)          | 572 (49.70%)          | 499 (42.98%)               | <0.001     |
| Age (years old)                  |                          |                        |                        |                            | <0.001     |
| 18–45                            | 564 (48.45%)             | 526 (45.54%)          | 589 (51.17%)          | 665 (57.28%)               |            |
| 45–60                            | 272 (23.37%)             | 316 (27.36%)          | 284 (24.67%)          | 263 (22.65%)               |            |
| ≥60                              | 328 (28.18%)             | 313 (27.10%)          | 278 (24.15%)          | 233 (20.07%)               |            |
| BMI (kg/m^2)                     |                          |                        |                        |                            | 0.715      |
| <18.5                            | 11 (0.90%)               | 21 (1.87%)            | 18 (1.72%)            | 33 (2.99%)                 |            |
| 18.5–25                          | 339 (27.79%)             | 310 (27.60%)          | 351 (33.59%)          | 341 (30.89%)               |            |
| 25–30                            | 435 (35.66%)             | 396 (35.26%)          | 338 (32.34%)          | 365 (33.06%)               |            |
| ≥30                              | 373 (30.57%)             | 426 (37.93%)          | 434 (41.53%)          | 412 (37.32%)               |            |
| Race                             |                          |                        |                        |                            | <0.001     |
| Mexican American                 | 198 (17.01%)             | 158 (13.68%)          | 192 (16.68%)          | 186 (16.02%)               |            |
| Other Hispanic                   | 126 (10.82%)             | 131 (11.34%)          | 109 (9.47%)           | 117 (10.08%)               |            |
| Non-Hispanic White               | 421 (36.17%)             | 466 (40.35%)          | 508 (44.14%)          | 560 (48.23%)               |            |
| Non-Hispanic Black               | 271 (23.28%)             | 282 (24.42%)          | 255 (22.15%)          | 223 (19.21%)               |            |
| Other Race                       | 148 (12.71%)             | 118 (10.22%)          | 87 (7.56%)            | 75 (6.46%)                 |            |
| Education                        |                          |                        |                        |                            | <0.001     |
| Below high school                | 258 (22.18%)             | 271 (23.46%)          | 319 (27.72%)          | 339 (29.27%)               |            |
| High school                      | 236 (20.29%)             | 255 (22.08%)          | 301 (26.15%)          | 286 (24.70%)               |            |
| Above high school                | 669 (57.52%)             | 629 (54.46%)          | 531 (46.13%)          | 533 (46.03%)               |            |
| Smoking status (yes, %)          |                          |                        |                        |                            | <0.001     |
| Never                            | 640 (57.92%)             | 608 (55.37%)          | 583 (54.38%)          | 552 (51.40%)               |            |
| Former                           | 276 (24.98%)             | 261 (23.77%)          | 245 (22.85%)          | 195 (18.16%)               |            |
| Current                          | 189 (17.10%)             | 229 (20.86%)          | 244 (22.76%)          | 327 (30.45%)               |            |
| Respiratory disease (yes, %)     | 128 (11.00%)             | 131 (11.34%)          | 142 (12.34%)          | 164 (14.13%)               | 0.016      |
| History of diabetes (yes, %)     | 114 (9.80%)              | 127 (11.01%)          | 120 (10.43%)          | 105 (9.04%)                | 0.470      |
| History of hypertension (yes, %) | 362 (31.10%)             | 364 (31.57%)          | 334 (29.07%)          | 316 (27.22%)               | 0.018      |
| Lung function impairment         | 155 (13.32%)             | 187 (16.19%)          | 200 (17.38%)          | 200 (17.23%)               | 0.007      |
| FeNO                             | 197 (17.78%)             | 183 (16.73%)          | 170 (15.47%)          | 168 (15.40%)               | 0.092      |
| Monocyte number (cells/uL)       | 510.29 ± 172.93          | 519.58 ± 178.28       | 540.40 ± 186.68       | 547.01 ± 193.75            | <0.001     |
| Neutrophils number (cells/uL)    | 4028.43 ± 1513.40        | 4172.29 ± 1756.88     | 4298.82 ± 1759.86     | 4537.27 ± 2918.24          | <0.001     |

ln(MBP/UCr), ln(mono-benzyl phthalate (ng/L)/urinary creatinine (g/dL)); MBP, mono-benzyl phthalate; lung function impairment, best test FEV1/FVC ratio below lower limit of normal and/or less than 70%; BMI, body mass index; FeNO, fractional exhaled nitrous oxide.

### 3.3. Effects of DBP Exposure on Lung Function Impairment and Blood Cells

We have performed a dose–response analysis of the relationship between ln(MBP/UCr) and lung function impairment. It was observed that the higher concentration of MBP in urine was consistent with higher risk of all of lung function impairment (Figure 2). However, the p-value for the nonlinear dose–response manner was insignificant ($P_{\text{nonlinear}} = 0.605$).

The associations of DBP exposure and lung function impairment among the four groups are shown in Table 3. The results were consistent whether confounding factors were adjusted or not, and participants in the highest vs. the lowest quartiles of ln(MBP/UCr) were found to be at increased risks of lung function impairment. After the full adjustment for confounders, the result of lung function impairment was significantly higher in the highest MBP group compared with the lowest MBP group (OR_{quartiles 4 vs. 1} = 1.35, 95% CI, 1.05–1.73; $P_{\text{trend}} = 0.017$). However, the results showed that there was no significant difference of FeNO between the highest MBP group vs. the lowest MBP group (OR_{quartiles 4 vs. 1} = 1.17, 95% CI, 0.92–1.50; $P_{\text{trend}} = 0.251$).
It was observed that the higher concentration of MBP, the higher risk of all respiratory diseases. The clinical characteristics were obtained by testing the null hypothesis of regression coefficient of the second spline was equal to zero. CI, confidence interval; MBP, mono-benzyl phthalate; OR, odds ratio.

Figure 2. Non-linear dose–response analysis on urinary MBP concentration and lung function impairment. Restricted cubic spline regression with three knots at the 10th, 50th, and 90th percentiles was used to explore the potential dose–response relationship between MBP and lung function impairment. The reference level was set at 6.31. A $P_{\text{non-linearity}}$ was obtained by testing the null hypothesis that regression coefficient of the second spline was equal to zero. CI, confidence interval; MBP, mono-benzyl phthalate; OR, odds ratio.

Table 3. Association between urinary MBP and the lung function impairment.

| Outcomes          | Model | Quartiles of ln(MBP/UCr), Range (Median) | $P_{\text{trend}}$ |
|-------------------|-------|----------------------------------------|-------------------|
| Lung function impairment | Model 1 | 1.00 (Reference) | 2.15–5.69 (5.23) | 0.007 |
|                   | Model 2 | 1.00 (Reference) | 5.69–6.31 (6.03) | 0.002 |
|                   | Model 3 | 1.00 (Reference) | 6.31–6.93 (6.59) | 0.015 |
|                   | Model 4 | 1.00 (Reference) | 6.93–10.20 (7.40) | 0.017 |
| High monocyte     | Model 1 | 1.00 (Reference) | 2.10 ± 2.09 | <0.001 |
|                   | Model 2 | 1.00 (Reference) | 2.15 ± 2.05 | <0.001 |
|                   | Model 3 | 1.00 (Reference) | 2.20 ± 2.13 | <0.001 |
|                   | Model 4 | 1.00 (Reference) | 2.29 ± 2.10 | <0.001 |
| High neutrophil   | Model 1 | 1.00 (Reference) | 1.37 (1.09, 1.72) | 0.011 |
|                   | Model 2 | 1.00 (Reference) | 1.36 (1.08, 1.73) | 0.011 |
|                   | Model 3 | 1.00 (Reference) | 1.34 (1.05, 1.72) | 0.011 |
|                   | Model 4 | 1.00 (Reference) | 1.31 (1.04, 1.59) | 0.022 |

The associations of MBP and four kinds of blood cells among the four groups are shown in Table 3 and Table S4. The results showed that there was significant difference of monocyte and neutrophil between higher MBP groups and quartiles 1 group. After the full adjustment for confounders, the ORs of higher monocytes and neutrophils were (OR quartiles 4 vs. 1 1.37, 95% CI, 1.02–1.84; $P_{\text{trend}}$ = 0.048) and (OR quartiles 4 vs. 1 1.66,
95% CI, 1.21–2.27; \( P_{\text{trend}} = 0.008 \), respectively, in the highest vs. the lowest quartiles of \( \ln(\text{MBP/UCr}) \).

### 3.4. Subgroup Analyses

The subgroup analyses on the associations of concentration of urinary MBP and lung function impairment (highest vs. the lowest quartiles of \( \ln(\text{MBP/UCr}) \)) are shown in Table 4. A significant interaction between urinary MBP and DDIR (\( P_{\text{interaction}} = 0.029 \)) and history of hypertension (\( P_{\text{interaction}} = 0.031 \)) was detected for lung function impairment. Specifically, the highest fourth of MBP was found to be associated with higher risks of lung function impairment (OR, quartiles 4 vs. 1, 1.64; 95% CI, 1.17–2.31) in people without hypertension; lower risk of lung function impairment (OR, quartiles 4 vs. 1, 1.06; 95% CI, 0.74–1.54) was found in participants with higher DDIR. However, no significant interaction was found for remaining predefined factors.

#### Table 4. Subgroup analyses on the association between urinary MBP and lung function impairment.

| Subgroup Variable | OR quartile 4 vs. 1 (95% CI) | \( p \) | \( P_{\text{interaction}} \) |
|-------------------|-----------------------------|------|-------------------|
| **Sex**           |                             |      |                   |
| woman             | 1.33 (0.90, 2.00)           | 0.160| 0.752             |
| man               | 1.35 (0.94, 1.93)           | 0.102|                   |
| **Age (years old)** |                             |      |                   |
| 18–45             | 1.20 (0.76, 1.90)           | 0.435|                   |
| 45–60             | 1.62 (0.94, 2.82)           | 0.082| 0.451             |
| ≥60               | 1.36 (0.88, 2.09)           | 0.166| 0.975             |
| **Race**          |                             |      |                   |
| Mexican American  | 1.07 (0.51, 2.26)           | 0.855|                   |
| Other Hispanic    | 4.25 (1.40, 14.53)          | 0.142| 0.309             |
| Non-Hispanic White| 1.57 (1.08, 2.29)           | 0.020| 0.406             |
| Non-Hispanic Black| 1.51 (0.85, 2.70)           | 0.161| 0.950             |
| Other Race        | 0.35 (0.06, 1.40)           | 0.172| 0.164             |
| **Education**     |                             |      |                   |
| Below high school | 1.45 (0.84, 2.54)           | 0.181|                   |
| High school       | 1.45 (0.84, 2.55)           | 0.183| 0.834             |
| Above high school | 1.40 (0.97, 2.04)           | 0.075| 0.625             |
| **History of diabetes** |                     |      |                   |
| No                | 1.46 (1.10, 1.94)           | 0.009|                   |
| Yes               | 0.84 (0.38, 1.85)           | 0.670| 0.126             |
| **Respiratory disease** |                     |      |                   |
| No                | 1.47 (1.09, 1.98)           | 0.012|                   |
| Yes               | 1.05 (0.58, 1.90)           | 0.933| 0.409             |
| **Smoke status**  |                             |      |                   |
| Never             | 1.70 (1.10, 2.63)           | 0.017|                   |
| Former            | 1.46 (0.87, 2.44)           | 0.154| 0.474             |
| Current           | 1.08 (0.68, 1.73)           | 0.748| 0.232             |
| **History of hypertension** |                   |      |                   |
| No                | 1.64 (1.17, 2.31)           | 0.006|                   |
| Yes               | 1.05 (0.68, 1.62)           | 0.999| 0.031             |
| **Daily dietary intake of riboflavin (mg)** |      |      |                   |
| Low/normal (≤1.8) | 1.85 (1.25, 2.75)           | 0.004|                   |
| Higher (>1.8)     | 1.07 (0.74, 1.54)           | 0.717| 0.026             |

\( \ln(\text{MBP/UCr}), \ln(\text{mono-benzyl phthalate(ng/L)/urinary creatinine(g/dL)}); \) MBP, mono-benzyl phthalate; lung function impairment, best test FEV1/FVC ratio below lower limit of normal and/or less than 70%; BMI, body mass index; ORs were adjusted for gender (man or woman), age (years old), race (Hispanic: Mexican American and other Hispanic, non-Hispanic: non-Hispanic White, non-Hispanic Black, and other race), education (below high school, high school, above high school), history of diabetes (yes or no), and hypertension (yes or no).

### 3.5. Relationship between DDIR and Lung Function Impairment Related with DBP Exposure

Two hundred and two participants were excluded due to the miss data of DDIR, and 4429 participants were included in the comprehensive subgroup analyses of the of DDIR (Table 5). These participants were divided into low/normal DDIR group (\( n = 2178 \) and...
higher DDIR group ($n = 2251$). The effects of MBP on lung function impairment, peripheral monocytes, and neutrophils were evaluated in the two groups, respectively. After the full adjustment for confounders, the result of lung function impairment was significantly higher in the highest MBP group compared with lowest MBP group ($OR_{quartiles 4 vs. 1} = 1.37, 95\% CI, 1.00–1.87; P_{trend} = 0.049$) in participants with low/normal DDIR but insignificantly higher in the highest vs. the lowest quartiles of MBP ($OR_{quartiles 4 vs. 1} = 1.30, 95\% CI, 0.97–1.75; P_{trend} = 0.119$) in participants with high DDIR.

Table 5. Association between urinary MBP and the lung function impairment, neutrophils, and monocytes in different level of daily dietary intake of riboflavin.

| Outcomes                  | Quartile of ln(MBP/UCr), Range (Median) | $P_{trend}$ |
|---------------------------|-----------------------------------------|-------------|
|                           | 2.15–5.69 (5.23)                         |             |
|                           | 5.69–6.31 (6.03)                         |             |
|                           | 6.31–6.93 (6.59)                         |             |
|                           | 6.93–10.20 (7.40)                        |             |
| Low/normal DDIR ($n = 2178$) |                                         |             |
| Lung function impairment  | Model 1 1.00 (Reference) 1.59 (1.12, 2.26) | 0.002       |
|                           | Model 2 1.00 (Reference) 1.43 (1.00, 2.05) | <0.001      |
|                           | Model 3 1.00 (Reference) 1.41 (0.97, 2.06) | 0.003       |
|                           | Model 4 1.00 (Reference) 1.41 (0.97, 2.06) | 0.002       |
|                           | Model 1 1.00 (Reference) 1.22 (0.91, 1.65) | <0.001      |
|                           | Model 2 1.00 (Reference) 1.27 (0.94, 1.72) | 0.003       |
|                           | Model 3 1.00 (Reference) 1.29 (0.93, 1.76) | 0.032       |
|                           | Model 4 1.00 (Reference) 1.26 (0.92, 1.73) | 0.018       |
|                           | Model 1 1.00 (Reference) 1.11 (0.80, 1.54) | 0.013       |
|                           | Model 2 1.00 (Reference) 1.12 (0.80, 1.56) | 0.021       |
|                           | Model 3 1.00 (Reference) 1.13 (0.80, 1.61) | 0.225       |
|                           | Model 4 1.00 (Reference) 1.14 (0.81, 1.62) | 0.193       |
|                           | Model 1 1.00 (Reference) 1.12 (0.80, 1.55) | 0.570       |
|                           | Model 2 1.00 (Reference) 1.14 (0.81, 1.61) | 0.350       |
|                           | Model 3 1.00 (Reference) 1.20 (0.84, 1.72) | 0.531       |
|                           | Model 4 1.00 (Reference) 1.17 (0.82, 1.66) | 0.616       |
|                           | Model 1 1.00 (Reference) 1.15 (0.87, 1.52) | 0.001       |
|                           | Model 2 1.00 (Reference) 1.07 (0.80, 1.42) | 0.024       |
|                           | Model 3 1.00 (Reference) 1.10 (0.81, 1.49) | 0.033       |
|                           | Model 4 1.00 (Reference) 1.16 (0.86, 1.56) | 0.195       |
|                           | Model 1 1.00 (Reference) 1.24 (0.93, 1.66) | 0.012       |
|                           | Model 2 1.00 (Reference) 1.21 (0.90, 1.63) | 0.031       |
|                           | Model 3 1.00 (Reference) 1.28 (0.94, 1.75) | 0.065       |
|                           | Model 4 1.00 (Reference) 1.34 (0.99, 1.83) | 0.049       |

ln(MBP/UCr), ln(mono-benzyl phthalate(ng/L)/urinary creatinine(g/dL)); MBP, mono-benzyl phthalate; lung function impairment, best test FEV1/FVC ratio below lower limit of normal and/or less than 70%; DDIR, daily dietary intake of riboflavin; high monocyte, the number of monocyte ≥1000 cells/ul or the monocyte percent ≥10%; high neutrophil, the number of neutrophil ≥7000 cells/ul or the monocyte percent ≥70%; Model 1, Unadjusted model; Model 2, Adjusted for gender (man or woman), age (years old), race (Mexican American, other Hispanic, Non-Hispanic White, Non-Hispanic Black, and other race), and education (below high school, high school, above high school); Model 3, adjusted for gender (man or woman), age (years old), race (Mexican American, other Hispanic, Non-Hispanic White, Non-Hispanic Black, and other race), education (below high school, high school, above high school), BMI (kg/m²); history of diabetes (yes or no), smoker status (never, former, current), and hypertension (yes or no); Model 4, adjusted for gender (man or woman), age (years old), race (Mexican American, other Hispanic, Non-Hispanic White, Non-Hispanic Black, and other race), education (below high school, high school, above high school), history of diabetes (yes or no), and hypertension (yes or no).

4. Discussion

In this national cross-sectional study, we revealed significant associations of concentration of urinary MBP with the risk of lung function impairment. Moreover, higher monocytes and neutrophils may contribute to lung function impairment associated with DBP exposure. Subgroup analyses further showed that these harmful associations between urinary MBP and lung function impairment were insignificant in people with high DDIR. High DDIR might reduce the neutrophil recruitment to alleviate the lung function impairment in the presence of DBP exposure.
Inhalation of DBP contributes to a large proportion of DBP intake due to the high concentration of DBP in indoor air. MBP is one of the main DBP metabolites [17], and MBP was the only significantly higher urinary phthalate metabolites in participants with lung function impairment compared with participants without lung function impairment in our study. The similar results of the harmful association between MBP and lung function impairment was shown in one previous study [18]. However, it was suggested that DBP exposure increased the early allergic response in that study, but the results of our studies showed that the FeNO and eosinophils were not significantly higher in the group with higher MBP than lower MBP. The inconsistency might be related with the small sample size in the previous study, which only included 16 participants.

In our study, we found that monocytes and neutrophils were higher in the high urinary MBP groups, and the trend of the changes in monocytes and neutrophils were also significant. Therefore, urinary MBP level was harmfully associated with changes in lung function and might be mediated by monocytes and neutrophils. One previous study reported the interaction between DBP and macrophages was mediated through PPARγ, which was highly expressed in macrophages [19,20]. As we know, the blood monocytes migrated into lung tissue and gave rise to interstitial and alveolar macrophages. Therefore, the changes of the peripheral monocytes might be related with the change of macrophages in lung effected by DBP [21]. It was reported that number of neutrophils in lavage fluid of mice in phthalates group was higher compared with the groups without phthalates [22]. Migration of blood neutrophils into the lung tissue is an important process of immune reaction, and neutrophils in lung tissue can also migrate into blood in patients with COPD [23]. It was reported that the phthalate treatment leaded to elevation of oxidant stress in neutrophils [24]. However, one previous study showed that riboflavin exerted both the antioxidant and anti-inflammatory effects against acetic acid-induced colonic inflammation by suppressing neutrophil accumulation, inhibiting reactive oxidant generation [25]. The decreasing level of TGFβ and TNF-α and the increasing level of glutathione in neutrophil may be the potential mechanism of antioxidant and anti-inflammatory effects of riboflavin [25,26]. Therefore, we speculated that high daily intake of riboflavin improves the lung function by suppressing neutrophil accumulation and inhibiting reactive oxidant generation induced by DBP exposure (Figure S1).

Interestingly, our subgroup analysis suggested that the lung function of participants with higher DDIR were less likely to be affected by DBP than patients with lower/normal DDIR. The relationship between riboflavin intake and lung function impairment associated with phthalates exposure is still unknown. Some previous studies suggested that riboflavin can suppress neutrophil accumulation, inhibit reactive oxidant generation, and improve oxidative DNA damage in a murine model of AA-induced colonic inflammation, sepsis and ischemia/reperfusion injury [25,27]. A similar result was also observed in our study. Suppressing neutrophil accumulation might be the main reason for the association of DDIR and lung function in the presence of DBP exposure.

There were several strengths in this study. Firstly, to our knowledge, this is the first population-based study to explore the relationship between DDIR and lung function impairment in the presence of DBP exposure. Secondly, we comprehensively analyzed the relationship between urinary MBP and lung function impairment and found the lung function impairment is associated with high levels of urinary MBP. Thirdly, this is the first study to reveal that the immuno-modulatory effects of riboflavin and changes of neutrophils might be the potential mechanism.

Limitations of this study should also be noted. Firstly, most measurements and questionnaires were completed at the same time, so we can only obtain clues rather than determine the direct causality in a large sample of population. Secondly, it is necessary to detect urinary MBP at different time points because the level of MBP at one time point cannot represent the long-term level of DBP exposure. Furthermore, we also need to follow up regarding the changes of lung function. Similarly, the 24 h dietary questionnaire made it difficult to accurately discern the persisting nutrition intake. Therefore, it is necessary
to complete a daily diet questionnaire during a long period. Thirdly, we also need to test the serum riboflavin concentration to explore the true riboflavin exposure because the riboflavin will be excreted through urine when it is beyond a certain level. Finally, the actual relationship between the number of monocytes and neutrophils in blood and in alveolar lavage fluid should be explored, and further study can focus on the neutrophil accumulation in lung tissue in an experimental murine model of lung function impairment associated with DBP exposure.

In summary, our study suggests that higher concentration of urinary MBP was associated with higher risk of lung function impairment, and the harmful association might be mediated by monocytes and neutrophils. A positive association between high DDIR and lung function in the presence of DBP exposure was observed in this study, and the inhibiting of the neutrophil recruitment might be the potential mechanism.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/nu14112282/s1, Table S1: The urinary phthalate metabolites of study population and the difference between groups with and without lung function impairment; Table S2: The blood cells of study population and the difference between groups with and without lung function impairment; Table S3: The blood cells of study population according to the concentration of urinary MBP; Table S4: Association between FeNO, eosinophil and urinary MBP; Figure S1: The potential biochemical and cell biological mechanisms of the riboflavin on lung function. Riboflavin exerted both the antioxidant and anti-inflammatory effects against acetic acid-induced colonic inflammation by suppressing neutrophil accumulation, inhibiting reactive oxidant generation. The decreasing level of TGF-β and TNF-α and increasing levels of glutathione in neutrophil may be the potential antioxidant and anti-inflammatory effects of riboflavin.

Author Contributions: J.L. conceptualized and designed the study, supervised data collection, carried out the initial analyses, and drafted the initial manuscript; S.C. and J.Z. designed the data collection instruments, collected data, and carried out the initial analyses; L.Z. (Lei Zhang), S.Y., J.W. and J.C. coordinated and supervised data collection, assisted in the statistical analysis, and carried out the initial analyses; M.T., Y.H. and S.T. coordinated and supervised data collection and critically reviewed the manuscript for important intellectual content. L.Z. (Liebin Zhao) and Y.Y. conceptualized and designed the study, supervised data collection, and reviewed and revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by health and family planning scientific research project of Pudong New Area Health Committee (PW2021E-06).

Institutional Review Board Statement: The NHANES concept was approved by the NCHS Research Ethics Review Board (ERB). Written informed consent was obtained from all individuals or their guardians. The study design was approved by the ethics committee of Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University and conducted according to the Declaration of Helsinki guidelines (SCMCIRB-W2022003).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: All of original data used in this study are freely available to the public. This data can be found here: https://www.cdc.gov/nchs/nhanes/ (accessed on 1 February 2022). All code of R software of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest: The authors have no conflict of interest to declare.

References
1. Eales, J.; Bethel, A.; Galloway, T.; Hopkinson, P.; Morrissey, K.; Short, R.; Garside, R. Human health impacts of exposure to phthalate plasticizers: An overview of reviews. Environ Int. 2022, 158, 106903. [CrossRef] [PubMed]
2. Silva, M.J.; Reidy, J.A.; Preau, J.L.; Samandar, E.; Needham, L.L.; Calafat, A.M. Measurement of eight urinary metabolites of di(2-ethylhexyl) phthalate as biomarkers for human exposure assessment. Biomarkers 2006, 11, 1–13. [CrossRef] [PubMed]
3. Casas, M.; Chevrier, C.; Hond, E.D.; Fernandez, M.F.; Pierik, F.; Philippat, C.; Slama, R.; Toft, G.; Vandentorren, S.; Wilhelm, M.; et al. Exposure to brominated flame retardants, perfluorinated compounds, phthalates and phenols in European birth cohorts: ENRICOeco evaluation, first human biomonitoring results, and recommendations. *Int. J. Hyg. Environ. Health* **2013**, *216*, 230–242. [CrossRef] [PubMed]

4. Wu, H.; Kupsco, A.; Just, A.; Calafat, A.M.; Oken, E.; Braun, J.M.; Sanders, A.P.; Mercado-Garcia, A.; Cantoral, A.; Pantic, I.; et al. Maternal Phthalates Exposure and Blood Pressure during and after Pregnancy in the PROGRESS Study. *Environ. Health Perspect.* **2021**, *129*, 127007. [CrossRef]

5. Gao, D.; Zou, Z.; Li, Y.; Chen, M.; Ma, Y.; Chen, L.; Wang, X.; Yang, Z.; Dong, Y.; Ma, J. Association between urinary phthalate metabolites and dyslipidemia in children: Results from a Chinese cohort study. *Environ. Pollut.* **2021**, *259*, 118632. [CrossRef]

6. Zeng, G.; Zhang, Q.; Wang, X.; Wu, K.H. Urinary levels of Phthalate metabolite mixtures and pulmonary function in adolescents. *Environ. Pollut.* **2022**, *293*, 118595. [CrossRef]

7. Schulz, C.O.; Rubin, R. Distribution, metabolism, and excretion of di-2-ethylhexyl phthalate in the rat. *Environ. Health Perspect.* **1973**, *3*, 123–129. [CrossRef]

8. Abdi, S.; Sobhanardakani, S.; Lorestani, B.; Cheraghhi, M.; Panahi, H.A. Analysis and health risk assessment of phthalate esters (PAEs) in indoor dust of preschool and elementary school centers in city of Tehran, Iran. *Environ. Sci. Pollut. Res. Int.* **2021**, *28*, 61151–61162. [CrossRef]

9. Kuo, P.L.; Hsu, Y.L.; Huang, M.S.; Tsai, M.J.; Ko, Y.C. Ginger suppresses phthalate ester-induced airway remodeling. *J. Agric. Food Chem.* **2011**, *59*, 3429–3438. [CrossRef]

10. Preece, A.S.; Knutz, M.; Lindh, C.H.; Bornehag, C.G.; Shu, H. Prenatal phthalate exposure and early childhood wheeze in the SELMA study. *J. Expo. Sci. Environ. Epidemiol.* **2021**, *32*, 303–311. [CrossRef]

11. Wang, X.; Han, B.; Wu, P.; Li, S.; Lv, Y.; Lu, J.; Yang, Q.; Li, J.; Zhu, Y.; Zhang, Z. Dibutyl phthalate induces allergic airway inflammation in rats via inhibition of the Nrf2/Thyl/JAK1 pathway. *Environ. Pollut.* **2020**, *267*, 115564. [CrossRef] [PubMed]

12. Zhou, S.; Han, M.; Ren, Y.; Yang, X.; Duan, L.; Zeng, Y.; Li, J. Dibutyl phthalate aggravated asthma-like symptoms through oxidative stress and increasing calcitonin gene-related peptide release. *Ecotoxicol. Environ. Saf.* **2020**, *199*, 110740. [CrossRef] [PubMed]

13. Ashoori, M.; Saedisomeilia, A. Riboflavin (vitamin B2) and oxidative stress: A review. *Br. J. Nutr.* **2014**, *111*, 1895–1911. [CrossRef] [PubMed]

14. Kim, T.; Choi, H.; Kim, J. Association between Dietary Nutrient Intake and Chronic Obstructive Pulmonary Disease Severity: A Nationwide Population-Based Representative Sample. *COPD J. Chronic Obstr. Pulm. Dis.* **2020**, *17*, 49–58. [CrossRef]

15. Hankinson, J.L.; Odencrantz, J.R.; Fedan, K.B. Spirometric reference values from a sample of the general U.S. population. *Am. J. Respir. Crit. Care Med.* **1999**, *159*, 179–187. [CrossRef]

16. Osorio Ovarian Tumor Tissue Analysis (OTTA) Consortium; Goode, E.L.; Block, M.S.; Kalli, K.R.; Vierkant, R.A.; Chen, W.; Fogarty, M.C.; Gentry-Maharaj, A.; Taloczko, A.; Hein, A.; et al. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. *JAMA Oncol.* **2017**, *3*, e173290. [CrossRef]

17. Sicińska, P. Di-n-butyl phthalate, butylbenzyl phthalate, and their metabolites exhibit different apoptotic potential in human peripheral blood mononuclear cells. *Food Chem. Toxicol.* **2019**, *133*, 110750. [CrossRef]

18. Maestre-Battle, D.; Huff, R.D.; Schwartz, C.; Alexis, N.E.; Tebbutt, S.J.; Turvey, S.; Belling, A.K.; Carlsten, C. Dibutyl Phthalate Augments Allergen-induced Lung Function Decline and Alters Human Airway Immunology. A Randomized Crossover Study. *Am. J. Respir. Crit. Care Med.* **2020**, *202*, 672–680. [CrossRef]

19. Gryttning, V.S.; Olderbergs, B.P.; Holme, J.A.; Samuelsen, J.T.; Solhaug, A.; Becher, R.; Belling, A.K. Di-n-butyl phthalate modifies PMA-induced macrophage differentiation of THP-1 monocytes via PPARγ. *Toxicol. Vitr.* **2019**, *54*, 168–177. [CrossRef]

20. Rajaram, M.V.; Brooks, M.N.; Morris, J.D.; Torrelles, J.B.; Azad, A.K.; Schlesinger, L.S. Mycobacterium tuberculosis activates human macrophage peroxisome proliferator-activated receptor gamma linking mannose receptor recognition to regulation of immune responses. *J. Immunol.* **2015**, *195*, 929–942. [CrossRef]

21. Evren, E.; Ringqvist, E.; Tripathi, K.P.; Sleiers, N.; Rives, I.C.; Gao, Y.; Sarhan, D.; Halle, T.; Sorini, C.; et al. Distinct differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* **2021**, *183*, e173290. [CrossRef]

22. Larsen, S.T.; Hansen, J.S.; Hansen, E.W.; Clausen, P.A.; Nielsen, G.D. Airway inflammation and adjuvant effect after repeated airborne exposures to di-(2-ethylhexyl)phthalate and ovalbumin in BALB/c mice. *Toxicology* **2007**, *235*, 119–129. [CrossRef] [PubMed]

23. Sapey, E.; Stockley, J.A.; Greenwood, H.; Ahmad, A.; Bayley, D.; Lord, J.M.; Insall, R.H.; Stockley, R.A. Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* **2011**, *183*, 1176–1186. [CrossRef] [PubMed]

24. Nadeem, A.; Ahmad, S.F.; Al-Harbi, N.O.; Al-Ayadhi, L.Y.; Alanazi, M.M.; Alfardan, A.S.; Attia, S.M.; Algahtani, M.; Bakheet, S. Dysregulated Nrf2 signaling in response to di(2-ethylhexyl) phthalate in neutrophils of children with autism. *Int. Immunopharmacol.* **2022**, *106*, 108619. [CrossRef] [PubMed]

25. Karakoyun, B.; Ertas, B.; Yüksel, M.; Akakin, D.; Çevik, Ö.; Şener, G. Ameliorative effects of riboflavin on acetic acid-induced colonic injury in rats. *Clin. Exp. Pharmacol. Physiol.* **2018**, *45*, 563–572. [CrossRef] [PubMed]
26. Seekamp, A.; Hultquist, D.E.; Till, G.O. Protection by vitamin B2 against oxidant-mediated acute lung injury. *Inflammation* 1999, 23, 449–460. [CrossRef]

27. Sanches, S.C.; Ramalho, L.N.; Mendes-Braz, M.; Terra, V.A.; Cecchini, R.; Augusto, M.J.; Ramalho, F.S. Riboflavin (vitamin B-2) reduces hepatocellular injury following liver ischaemia and reperfusion in mice. *Food Chem. Toxicol.* 2014, 67, 65–71. [CrossRef]